TORNTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | TORNTPHARM | Market Cap | 1,53,668 Cr. | Current Price | 4,540 ₹ | High / Low | 4,714 ₹ |
| Stock P/E | 68.5 | Book Value | 250 ₹ | Dividend Yield | 0.84 % | ROCE | 20.1 % |
| ROE | 28.0 % | Face Value | 5.00 ₹ | DMA 50 | 4,298 ₹ | DMA 200 | 3,961 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 504 Cr. | PAT Prev Qtr | 584 Cr. |
| RSI | 60.9 | MACD | 76.6 | Volume | 2,23,938 | Avg Vol 1Wk | 4,52,910 |
| Low price | 3,102 ₹ | High price | 4,714 ₹ | PEG Ratio | 2.29 | Debt to equity | 1.69 |
| 52w Index | 89.2 % | Qtr Profit Var | 2.49 % | EPS | 64.8 ₹ | Industry PE | 31.6 |
📊 Current Price: 4,540 ₹
🛒 Optimal Buy Price: 4,520 – 4,550 ₹ (near 50 DMA support)
🎯 Profit Exit Levels: 4,600 ₹ / 4,660 ₹
🛑 Stop-Loss: 4,490 ₹
⏳ If already holding: Exit near 4,600–4,660 ₹ if RSI weakens below 59 or MACD momentum fades; tighten stop-loss if price slips under 4,520 ₹ with declining volume.
Positive
✔️ EPS at 64.8 ₹ supports strong earnings visibility.
✔️ ROCE at 20.1% and ROE at 28.0% show excellent operational efficiency.
✔️ Price above both 50 DMA (4,298 ₹) and 200 DMA (3,961 ₹), confirming bullish trend.
✔️ RSI at 60.9 indicates healthy momentum.
✔️ MACD positive (76.6), supporting short-term bullish bias.
✔️ Institutional support with FII holdings increasing (+0.05%).
Limitation
⚠️ P/E at 68.5 vs industry PE of 31.6 highlights significant valuation premium.
⚠️ Dividend yield at 0.84% is modest.
⚠️ Debt-to-equity ratio at 1.69 indicates high leverage risk.
⚠️ Volume (2.2 Lakh) below weekly average (4.5 Lakh), limiting intraday liquidity.
⚠️ PAT declined sequentially (504 Cr. vs 584 Cr.), showing earnings pressure.
Company Negative News
❌ Sequential profit decline highlights weakening profitability.
❌ DII holdings reduced (-0.09%), showing lower domestic support.
❌ High leverage raises financial risk.
Company Positive News
✅ EPS remains strong relative to peers.
✅ FII inflows show foreign investor confidence.
✅ Price trading well above key moving averages, supporting bullish bias.
✅ Quarterly profit variation at +2.49% year-on-year shows resilience.
Industry
🌐 Industry PE at 31.6 vs TORNTPHARM’s 68.5, showing valuation premium.
💊 Pharma sector outlook remains positive with steady demand for healthcare and specialty drugs.
Conclusion
⚖️ TORNTPHARM shows moderate intraday potential with strong fundamentals and bullish technicals.
📉 Valuation premium, high debt, and weaker liquidity limit upside momentum.
🎯 Suitable for disciplined intraday trades targeting 4,600–4,660 ₹, with strict stop-loss at 4,490 ₹.
Would you like me to extend this into a pharma sector overlay with peer benchmarking (e.g., Sun Pharma, Cipla, Dr. Reddy’s) to compare TORNTPHARM’s intraday strength against its industry peers?